Compare ICICI Bank Limited Common Stock (IBN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ICICI Bank Limited Common Stock vs Tango Therapeutics Inc. — how do they compare? ICICI Bank Limited Common Stock trades at $28.61 (market cap $100.86B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: ICICI Bank Limited Common Stock is far larger — about 27× Tango Therapeutics Inc.'s market cap, and ICICI Bank Limited Common Stock pays a 0.89% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold ICICI Bank Limited Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| IBN | TNGX | |
|---|---|---|
Market Cap | $100.86B | $3.74B |
Volume | 5,968,041 | 3,438,781 |
Sector | Financials | Health |
52-Week High | $32.94 | $32.90 |
52-Week Low | $25.20 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.27T | $2.76B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBN trades at $28.54, up 1.75% today, showing strong momentum with recent earnings beats in Q1 and Q2 2026. The stock maintains robust fundamentals including a 24.8% net income margin and 15.8% ROE, supported by $2.05T revenue in 2025. Technical indicators show bearish signals despite unanimous analyst buy ratings, with RSI suggesting potential overbought conditions near current levels.
The outlook remains positive given strong profitability metrics and analyst consensus, but technical weakness and high valuation multiples (P/E 17.85, P/S 4.43) present near-term risks. Investors should monitor Q3 2026 earnings results against expectations of $0.40 EPS for continued fundamental confirmation.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ICICI Bank Limited Common Stock
ICICI Bank is an Indian financial services company providing banking, lending, cards, insurance, and investment products. It serves retail, business, and corporate customers.
Read more on IBN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
